Genetically modified herpes virus delivers one-two punch against advanced cancers
A new genetically engineered virus has delivered a one-two punch against advanced cancers in initial findings from a phase I trial.
Sep 23, 2022
0
3410
Amino Acids, Peptides, and Proteins: News and Research on Nivolumab
MeSH tree: D12.776.124.486.485.114.224.060.829
Experimental test promises to predict side-effects and cancer's return in patients treated with immunotherapy
A single research test has the potential to predict which patients treated with immunotherapies—which harness the immune system to attack cancer cells—are likely to have their cancer recur or have severe side effects, a new ...
Sep 15, 2022
0
90
Adjuvant nivolumab + ipilimumab lacks efficacy for localized renal cell carcinoma
Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse, according ...
Sep 14, 2022
0
43
Study results offer new hope for advanced lung cancer patients being treated with immunotherapy
Patients with advanced lung cancer had a better chance at survival when their treatment combined chemotherapy with a drug designed to turn the immune system against cancer, according to two studies released Sunday at a conference ...
Sep 12, 2022
0
89
Researcher identifies effective combination immunotherapy for subgroup of patients with metastatic colorectal cancer
A physician-scientist at City of Hope, one of the largest cancer research and treatment organizations in the United States, has identified a novel combination immunotherapy regimen that demonstrated significant response in ...
Sep 12, 2022
0
73
Dual checkpoint inhibitor blockade shows promise as first-line and salvage therapy for Merkel cell carcinoma patients
Merkel cell carcinoma is a rare but aggressive form of skin cancer that has a high rate of metastasis and poor patient outcomes. The current standard of care for patients with recurrent, unresectable or metastatic disease ...
Sep 12, 2022
0
54
First randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients with kidney cancer. Patients with high-risk renal ...
Sep 8, 2022
0
57
Three-drug combination slows progression of advanced kidney cancer
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer ...
Sep 8, 2022
0
69
Consolidation nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiation for patients with NSCLC
Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with ...
Aug 8, 2022
0
45
NADIM II trial provides support for neoadjuvant chemoimmunotherapy for patients with non-small cell lung cancer
In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer. Today, the researchers from the NADIM trial present new data ...
Aug 8, 2022
0
56
